Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 720 DKK -1.1%
Market Cap: 50.9B DKK
Have any thoughts about
Zealand Pharma A/S?
Write Note

Zealand Pharma A/S
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zealand Pharma A/S
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Zealand Pharma A/S
CSE:ZEAL
Total Current Assets
kr8.7B
CAGR 3-Years
88%
CAGR 5-Years
41%
CAGR 10-Years
38%
Genmab A/S
CSE:GMAB
Total Current Assets
kr21.9B
CAGR 3-Years
3%
CAGR 5-Years
23%
CAGR 10-Years
23%
Ascendis Pharma A/S
NASDAQ:ASND
Total Current Assets
€973.7m
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
58%
B
Bavarian Nordic A/S
CSE:BAVA
Total Current Assets
kr5.4B
CAGR 3-Years
15%
CAGR 5-Years
23%
CAGR 10-Years
23%
Bioporto A/S
CSE:BIOPOR
Total Current Assets
kr123.9m
CAGR 3-Years
9%
CAGR 5-Years
13%
CAGR 10-Years
11%
Saniona AB
STO:SANION
Total Current Assets
kr74.2m
CAGR 3-Years
-46%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
No Stocks Found

Zealand Pharma A/S
Glance View

Market Cap
50.9B DKK
Industry
Biotechnology

Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.

ZEAL Intrinsic Value
201.52 DKK
Overvaluation 72%
Intrinsic Value
Price

See Also

What is Zealand Pharma A/S's Total Current Assets?
Total Current Assets
8.7B DKK

Based on the financial report for Sep 30, 2024, Zealand Pharma A/S's Total Current Assets amounts to 8.7B DKK.

What is Zealand Pharma A/S's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
38%

Over the last year, the Total Current Assets growth was 343%. The average annual Total Current Assets growth rates for Zealand Pharma A/S have been 88% over the past three years , 41% over the past five years , and 38% over the past ten years .

Back to Top